Transaction · 0000950170-25-008348

Curran Terrie

Curran Terrie, PRES, CE, reported an open-market or private sale at Phathom Pharmaceuticals, Inc. involving 19109.000000 shares for an estimated $125884.36. Reported holdings after the transaction were 360465.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code SPRES, CE
PHATPhathom Pharmaceuticals, Inc.
Filing timeJan 23
Trade dateJan 21, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

PHAT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PHAT since 2025-01-23Filed 589 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0000950170-25-008348
Common Stock
Transaction date
Jan 21, 2025
Filed Jan 23, 2025, 09:19 PM · 2d delay
Shares
19.1k sh
$659 per share
Estimated value
-$12.5M
Computed from shares × price
Holdings after
360k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President and Chief Executive

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

  2. F2

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6503. The reporting person undertakes to provide Phatho…

  3. F3

    Includes 1,840 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.

Original filing · 0000950170-25-008348
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PHAT